MX2010002046A - Tratamiento de cancer de pulmon. - Google Patents

Tratamiento de cancer de pulmon.

Info

Publication number
MX2010002046A
MX2010002046A MX2010002046A MX2010002046A MX2010002046A MX 2010002046 A MX2010002046 A MX 2010002046A MX 2010002046 A MX2010002046 A MX 2010002046A MX 2010002046 A MX2010002046 A MX 2010002046A MX 2010002046 A MX2010002046 A MX 2010002046A
Authority
MX
Mexico
Prior art keywords
lung cancer
treatment
administered
inhibit
treat
Prior art date
Application number
MX2010002046A
Other languages
English (en)
Spanish (es)
Inventor
Cynthia W Tuthill
Original Assignee
Sciclone Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sciclone Pharmaceuticals Inc filed Critical Sciclone Pharmaceuticals Inc
Publication of MX2010002046A publication Critical patent/MX2010002046A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
MX2010002046A 2007-08-23 2008-08-21 Tratamiento de cancer de pulmon. MX2010002046A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US95753007P 2007-08-23 2007-08-23
PCT/US2008/009932 WO2009025830A1 (en) 2007-08-23 2008-08-21 Treatment of lung cancer

Publications (1)

Publication Number Publication Date
MX2010002046A true MX2010002046A (es) 2010-05-03

Family

ID=40378469

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010002046A MX2010002046A (es) 2007-08-23 2008-08-21 Tratamiento de cancer de pulmon.

Country Status (14)

Country Link
US (1) US20110189305A1 (enExample)
EP (1) EP2192835A4 (enExample)
JP (1) JP2010536854A (enExample)
KR (1) KR20100063078A (enExample)
CN (1) CN101842009A (enExample)
AU (1) AU2008289522A1 (enExample)
BR (1) BRPI0815772A2 (enExample)
CA (1) CA2697261A1 (enExample)
EA (1) EA201070295A1 (enExample)
MX (1) MX2010002046A (enExample)
NZ (1) NZ584065A (enExample)
UA (1) UA98508C2 (enExample)
WO (1) WO2009025830A1 (enExample)
ZA (1) ZA201001876B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2519738C2 (ru) * 2011-12-12 2014-06-20 Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения и социального развития Российской Федерации Способ лечения рака легкого

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2009008641A (es) 2007-02-13 2009-09-14 Sciclone Pharmaceuticals Inc Composiciones para el tratamiento o prevencion del deterioro, lesion o daño a tejido debido a enfermedad de las mucosas.

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5902790A (en) * 1995-10-03 1999-05-11 Cytran, Inc. Pharmaceutical angiostatic dipeptide compositions and method of use thereof
US5916878A (en) * 1995-11-28 1999-06-29 Edward T. Wei γ-glutamyl and β-aspartyl containing immunomodulator compounds and methods therewith
US5744452A (en) * 1995-11-28 1998-04-28 Edward T. Wei γ-L-glutamyl containing immunomodulator compounds and methods therewith
RU2141483C1 (ru) * 1997-07-04 1999-11-20 Небольсин Владимир Евгеньевич Производные пептидов или их фармацевтически приемлемые соли, способ их получения, применение и фармацевтическая композиция
RU2229892C2 (ru) * 2001-06-08 2004-06-10 Государственное учреждение "Санкт-Петербургский научно-исследовательский институт фтизиопульмонологии" Способ лечения туберкулеза легких

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2519738C2 (ru) * 2011-12-12 2014-06-20 Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения и социального развития Российской Федерации Способ лечения рака легкого

Also Published As

Publication number Publication date
ZA201001876B (en) 2010-11-24
CN101842009A (zh) 2010-09-22
EP2192835A1 (en) 2010-06-09
EP2192835A4 (en) 2010-11-10
WO2009025830A1 (en) 2009-02-26
AU2008289522A1 (en) 2009-02-26
US20110189305A1 (en) 2011-08-04
BRPI0815772A2 (pt) 2014-09-30
NZ584065A (en) 2012-03-30
JP2010536854A (ja) 2010-12-02
KR20100063078A (ko) 2010-06-10
UA98508C2 (ru) 2012-05-25
CA2697261A1 (en) 2009-02-26
EA201070295A1 (ru) 2010-10-29

Similar Documents

Publication Publication Date Title
TN2009000400A1 (en) Methods of treating cancer using pyridopyrimidininone inhibitors of pi3k alpha
UA98141C2 (ru) Способы лечения с применением хинаксолиновых ингибиторов pi3k-альфа
JO2848B1 (en) Organic compounds
EP2294184A4 (en) TREATMENT OF EYE DISEASES AND EXCESSIVE NEOVASCULARIZATION WITH THE HELP OF COMBINED THERAPY
MX2011008221A (es) Tratamiento de cancer de pulmon con un compuesto de nitrobenzamida en combinacion con un inhibidor de un factor de crecimieno.
MY146111A (en) Acylaminopyrazoles as fgfr inhibitors
TN2010000208A1 (en) Treatment of breast cancer with a parp inhibitor alone or in combination with anti-tumor agents
EA201270570A1 (ru) Комбинированная терапия раковых заболеваний с помощью соединений-ингибиторов hsp90
MX2009003362A (es) Uso de interleucina-10 pegilada para tratamiento de cancer.
TN2012000401A1 (en) Heterocyclic compound
TN2013000227A1 (en) Use of sigma ligands in bone cancer pain
MX2011011083A (es) Compuestos heterociclicos como inhibidores de mek.
MX2009009574A (es) Tratamiento de melanoma.
UA107204C2 (uk) Протигрибкова композиція, що містить грибковий організм pythium oligandrum
JO3145B1 (ar) مركبات مفيدة لتثبيط chk1
PH12013500559A1 (en) Combination therapy for treating hcv infection
MX2014000150A (es) Sistemas, metodos y formulaciones para tratamiento de cancer.
WO2010121675A3 (en) Thiazolyl-benzimidazoles
MX348758B (es) Derivados de sanglifehrina y metodos para su produccion.
MX2011009804A (es) Una dosis de ave5026 para el tratamiento de tromboembolismo venoso en pacientes con deterioro renal severo.
WO2010014798A3 (en) Pyrimidotriazinediones and pyrimidopyrimidinediones and methods of using the same
MX2012000203A (es) Procedimientos de uso del factor liberador de corticotropina para el tratamiento de cancer.
EA201070295A1 (ru) Лечение рака легких
MX2011006532A (es) Compuestos anticancerigenos.
WO2007123847A3 (en) Treatment of melanoma

Legal Events

Date Code Title Description
FA Abandonment or withdrawal